172.4K views | +366 today

Cartographie des métiers du digital en 2016 - Blog du Modérateur


Comme l’an dernier, l’IAB a présenté son étude sur les “métiers et compétences du marketing et de la communication dans un contexte de transition digitale”
No comment yet.

Sanofi mise sur l’intelligence artificielle pour offrir une médecine personnalisée - L'Usine de la Santé


Le laboratoire français Sanofi attend de sa co-entreprise fondée avec Google qu’elle sorte un prototype de traitements intégrés du diabète... - L'Usine de la Santé
No comment yet.

Médicament : le marché des bio-similaires s'ouvre


Ces « génériques » issus de la biologie coûtent environ 25 % moins cher. Pendant des années, la progressio
No comment yet.

Medisafe Expands Pharma Offering: "Way Beyond the Pill" Tackles Four Leading Pharma Challenges


PHILADELPHIA, Oct. 10, 2016 /PRNewswire/ -- Medisafe Expands Pharma Offering: 'Way Beyond the Pill' Tackles Four Leading Pharma Challenges. Compan
No comment yet.

Pack to the future | Special Report: Technology


The relationship between packaging and technology means much more these days than a box with a smart phone in it. Tony Corbin reports
No comment yet.

D’après McKinsey, la révolution numérique des entreprises françaises : c’est (vraiment) maintenant !


Quand on parle du numérique, on pense technologies : Internet, Big Data, Cloud, Robotique avancée… McKinsey a évalué la valeur économique potentielle d’un plein déploiement des technologies numériques en enquêtant auprès de 500 entreprises. Résumé.
No comment yet.

How digital disruption will affect your industry


This Bain & Company interactive explores how digital disruption is affecting different industries and how leading companies are using digital to change their own businesses.
No comment yet.

L’entrepreneuriat en santé, une chance historique pour l’industrie française #hcsmeufr


LE CERCLE/POINT DE VUE – De nouvelles filières et acteurs vont émerger dans le secteur de la santé grâc
No comment yet.

Interview de Philippe Lamoureux à l'ouverture du GIMRA, le 13.10.2016, Clermont-Ferrand | LEEM - Les entreprises du médicament


5èmes Journées du GIMRA (Groupement des industries de santé et du médicament de la Région Auvergne), 12-13 octobre 2016 à Clermont-Ferrand su
No comment yet.

Can social media help us hear patients?


A growing number of people turn to the Internet for information on healthcare. More and more of them also use social media—like Twitter and Facebook—to share their personal experiences—whether it’s rating their healthcare provider or discussing their medicines.

Understanding the benefits and risks of medicine from a patient’s point of view is important to the evaluation of our medicines.

"We need to hear from patients about their experiences with our medicines,” says Dr. Murray Stewart, Chief Medical Officer for GSK, who is charged with looking out for patient health and safety when it comes to GSK’s medicines. “Social media presents an opportunity to listen in a much more immediate and direct way than we’ve used in the past.”

We set out recently to find new ways to tap into the information patients share about their ‘real-world’ experience with our medicines.

Real-time safety data

With the help of digital experts from outside GSK, we began to analyze publicly available internet posts, filtering out unrelated information and anything that would identify individuals to GSK.

In a 2-year period, we found approximately 22 million Twitter and Facebook posts discussing potential adverse events for 1,000 medicines. Compare this figure to the 8.6 million adverse event reports received by the  U.S. Food and Drug Administration’s Adverse Event Reporting System (FAERS) since 1968, and the size of the challenge becomes clear.

Real-time benefits data

An additional evaluation of 15 medicines showed that 26% of posts also mentioned the benefits of taking the medicine and useful information around how long a medicine took to work, how long the effects last, and how it compared to other treatment options.

Monitoring social media when one of our inhaled allergy medicines became available over the counter was also hugely helpful. The feedback enabled  us to understand how well the product worked for patients when their healthcare professionals were no longer involved in choosing the medicine or giving instructions on dosing.

Protecting patients through social listening

Social media posts have also helped us to evaluate and characterise abuse of a medicine, for example reports of crushing tablets that were meant to be swallowed and then consuming them in other ways such as by injection or inhalation. Being aware of common misuse of treatments helps us to make decisions on appropriate labeling and further guidance.

More opportunities to explore

While we’ve come a long way in our use of social media, there is still a lot of work to do to fully understand the strengths and weaknesses of this data and to establish best practices. For example, we are working to create automated tools that can sort through very large volumes of information and identify urgent issues so they are addressed quickly.

We believe people will continue to use social media to share their experiences with medications. By paying attention to comments -- whether they are about the benefits or about potential drawbacks – social media can help us to understand the full context of patient experiences. We’re excited by the potential of social media to improve our patient care and we can’t wait to see where it may take us next.

No comment yet.

La transformation digitale à l'épreuve de la résistance au changement - Le Monde Informatique


Transformation numérique : Dans leur deuxième baromètre des pratiques digitales, Sia Partners, Econocom et l'Ifop pointent les difficultés des entreprises à s'ouvri
No comment yet.

Video Is Increasingly Important in Content Marketing #Infographic


Social media changed the way we communicate, and visual content on social is changing the way we consume information. Visual content leads to higher engagement than all-text content, and video is becoming an increasingly important piece of the social media marketing engagement puzzle.
LATM - L'Atelier Transmedia's curator insight, October 20, 3:34 AM
D'ici 2019, la vidéo représentera 80% du contenu webmarketing. Et vous, vous vous y mettez quand ?
David Picard Roussel's curator insight, October 20, 8:12 AM

[ Aux petite PMEs ] Cette infographique explique bien l'importance du visuel.

JNJ Innovation Aims to Develop Breakthrough Medical Device Technologies


Johnson & Johnson Innovation LLC (JJI) today announced the creation of the Center for Device Innovation at Texas Medical Center (CDI @ TMC), a broad, new collaboration between JJI and TMC that aims to accelerate end-to-end development of breakthrough medical devices. This expands on JJI’s collaboration with TMC established earlier this year with the opening of JLABS @ TMC, combining the resources of the world’s largest medical complex with the capabilities of the Johnson & Johnson Medical Devices Companies*, to advance the health and well-being of people around the globe.


The CDI @ TMC will include multiple components that will accelerate the development of new medical technologies from concept through commercialization, including a new medical device engineering studio housed at the TMC Innovation Institute. This state-of-the-art “maker space” will be home to R&D staff of the Johnson & Johnson Medical Devices Companies and will be used to accelerate both select internal projects and strategically aligned ventures of JJI partner companies.

Pharma Guy's curator insight, October 18, 1:06 PM

Related article: “Johnson & Johnson Expands Its Membership in the Digital Innovation Club”;

Siemens, IBM Watson partner for Population Health Management


BM Watson Health and Siemens Healthineers announced a five-year global health-focused alliance in Population Health Management (PHM) to enhance care delivery and control the cost of care.
No comment yet.

Interview de Philippe Lamoureux @leemfrance sur la "e"transfo des industriels du médicament #hcsmeufr #gimra2016


5èmes Journées du GIMRA (Groupement des industries de santé et du médicament de la Région Auvergne), 12-13 octobre 2016 à Clermont-Ferrand su
Lionel Reichardt / le Pharmageek:

Une production"Pharmageek"...merci au LEEM pour sa réactivité :-)

No comment yet.

Science 37 raises $31M from Sanofi, others for mobile clinical trials offering


Science 37, which connects willing individuals to researchers so they can participate in trials from their homes, has raised $31 million in Series B funding. Previously, the company raised $6.5 million.The round was led by Redmile Group, with participation from Lux Capital and Sanofi Genzyme BioVentures, the latter of which will also provide Science 37 with technical and strategic guidance. The funding will be used to help the company further develop its technology and continue to expand into new therapeutic areas.

No comment yet.

Celgene & Sage Bionetworks Plan Real-world Anemia Observational Study Using Apple's ResearchKit


Celgene is planning to use Apple's ResearchKit framework for an observational study into the burden of chronic anaemia in two blood disorders.


Working on the project with biomedical research organisation Sage Bionetworks, Celgene aims to collect difficult-to-quantify data in myelodysplastic syndromes and beta-thalassemia.


The partners' mobile study will also collect neurological assessments of patients using cognitive testing software from BrainBaseline, technology that allows self-assessment of cognitive performance.


Celgene said its app would additionally support patients living with their disease and allow them to understand their physical functioning and other symptoms of anaemia.


Michael Pehl, president of hematology and oncology for Celgene, said: "We stand at a point where technology is unlocking the ability to capture patient reported outcomes.


"Through our collaboration with Sage Bionetworks and the evolving capability of smartphones and wearables as robust data collection devices, we believe we will be able to provide important new insights for patients with MDS and beta-thalassemia."

Myelodysplastic syndromes and beta-thalassemia typically have clinical endpoints outside traditional measures.


The project will see Celgene and Sage work with patient groups the MDS Foundation and Cooleys Anemia Foundation on defining the right elements for the mobile app to capture in order to ensure it is relevant for patients.

#FDA Publishes New Draft Guidance on Software as a Medical Device (SaMD).


The FDA has entered into the federal register a new draft guidance  pertaining to "software as a medical device" (SaMD). The guidance is presented as representing the FDA's current thinking on establishing clinical evaluation guidelines for SaMD, but is written by an international organization of device regulators, the International Medical Device Regulators Forum, of which FDA is a member.


The guidance seeks to articulate what's new and different about SaMD (a category which would include mobile medical apps) and provide a stratified guidance on how to regulate different kinds of software and what kind of evidence is needed for each regulatory category. The guidance stratifies devices on two axes: whether the device informs care, drives care, or treats/diagnoses and whether the condition in question is non-serious, serious, or critical. So software that treats or diagnoses a critical condition is in the highest risk category, while software that informs care about a non-serious condition is in the lowest.


The guidelines also call out and address the fact that software development tends to move faster than traditional medical device development and can more easily be influenced by postmarket data.


"SaMD ... is unique in that it operates in a complex highly connected-interactive socio-technical environment in which frequent changes and modifications can be implemented more quickly and efficiently," the guidance says. "Development of SaMD is also heavily influenced by new entrants unfamiliar with medical device regulations and terminology developing a broad spectrum of applications."

Pharma Guy's curator insight, October 18, 7:26 AM

Related article: “Is SaaD - Software as a Drug - the Next Big Thing in mHealth?”;

rob halkes's curator insight, October 18, 7:39 AM

Via @pharmaguy The New #FDA draft guidance on software as a Medical Device (SaMD)

Le chef de projet digital, ce grand organisateur tout-terrain !


INFOGRAPHIE + TÉMOIGNAGE // Transformation digitale oblige, les entreprises ne peuvent plus se passer de ces “traducteurs” entre les métiers et les développeurs. Si vous aimez coordonne
Philippe MATHIEU's curator insight, October 12, 4:48 PM
le chef de projet digital, le nouveau pilote de vos projets de transformation numérique

Top 10 Pharma Companies of 2016 | The Lists


The top 10 pharmas on this year’s GEN List generated a combined $1.568 trillion in market cap, down 3.7% from the $1.626 trillion racked up by the drug developers on last year’s GEN List.
No comment yet.

Which drugmakers have the healthiest presence on social media?


Ogilvy Healthworld tracked the activity of the 20 largest global companies' Instagram, Facebook, Twitter, and YouTube channels from January to June, using audience intelligence platform Pulsar Core.

In the above graph from its report, The Social Check-up, the number of posts is measured on the x-axis. Lilly was the most prolific poster and so appears furthest to the right, dwarfing infrequent publishers Allergan, Teva Pharmaceutical Industries, and Takeda Pharmaceuticals.

See also: 8 ways for pharma to improve the way it uses Twitter

However, Lilly's posting did not always create engagement. It posted nearly twice as much as Boehringer Ingelheim and seven times as much as Novo Nordisk. These two firms scored highly on an engagement ranking calculated around likes, shares, comments, and retweets, shown on the y-axis.

The size of the dots relates to size of social media following — Johnson & Johnson has the largest.

See also: Omitting risk info in ads is top reason for FDA warning

The report says: "The rise of paid social has offered companies the ability to achieve better user response rates through highly specific content targeting. It is difficult to speculate which of the pharma companies studied were using paid social strategies. This may be one of the reasons Novo Nordisk and Boehringer Ingelheim achieved significantly higher levels of engagement compared with their competitors."

Another finding of the report is that disease awareness was the most common content theme posted by pharma firms, but their audiences actually preferred to interact with company news and CSR-related content.

Ruth Whittington's curator insight, October 14, 8:58 AM
Pharma and social media: which company comes out on top?

10 commandements pour réussir un projet social media dans la santé


Découvrez en infographie les bonnes pratiques à suivre pour réussir un projet social media dans le domaine de la santé en 10 commandements.
No comment yet.

Will eDetailing Spell the Death of Traditional In-person #Pharma Sales Details?


Big pharmaceutical companies have found replacements for the army of sales representatives they've laid off in recent years: digital sales tools that seek to sell doctors on drugs without the intrusion of an office visit


"You can't eat the orange and throw the peel away - a man is not a piece of fruit," says Willy Loman in Act 2 of Death of a Salesman. Today, many pharma sales reps may be feeling like tossed peeled fruit.


eDetailing in one form or another seems to be making a comeback since the recession hit the drug industry in 2007 and 2008 (see chart on right). I'm not really sure which is the "chicken" and which is the "egg"; ie, whether an uptick in adoption of eDetailing technology lead to the recent layoff of pharma reps or if reps were laid off because of the economy and subsequently replaced by machines.


Despite the title of this post, reports of the death of pharma "salesmen" may be somewhat exaggerated and not all sales reps can be replaced by machines.

No comment yet.